CO2019004756A2 - Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño - Google Patents
Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueñoInfo
- Publication number
- CO2019004756A2 CO2019004756A2 CONC2019/0004756A CO2019004756A CO2019004756A2 CO 2019004756 A2 CO2019004756 A2 CO 2019004756A2 CO 2019004756 A CO2019004756 A CO 2019004756A CO 2019004756 A2 CO2019004756 A2 CO 2019004756A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- disorders
- treatment
- procedure
- obtaining
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 abstract 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 abstract 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 abstract 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 abstract 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- -1 benzimidazole derivative compounds Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002060 circadian Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| PCT/BR2017/050320 WO2018076090A1 (en) | 2016-10-24 | 2017-10-23 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004756A2 true CO2019004756A2 (es) | 2019-05-21 |
Family
ID=62023150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004756A CO2019004756A2 (es) | 2016-10-24 | 2019-05-09 | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (enExample) |
| EP (2) | EP3529234B1 (enExample) |
| JP (1) | JP7194683B2 (enExample) |
| KR (1) | KR102594251B1 (enExample) |
| CN (2) | CN110088092B (enExample) |
| AR (1) | AR109467A1 (enExample) |
| AU (1) | AU2017351756B2 (enExample) |
| BR (1) | BR102016024814A2 (enExample) |
| CL (1) | CL2019001105A1 (enExample) |
| CO (1) | CO2019004756A2 (enExample) |
| DK (1) | DK3529234T3 (enExample) |
| EC (1) | ECSP19032963A (enExample) |
| ES (2) | ES2970546T3 (enExample) |
| FI (1) | FI3529234T3 (enExample) |
| MX (1) | MX392990B (enExample) |
| PE (2) | PE20250558A1 (enExample) |
| PT (1) | PT3529234T (enExample) |
| SG (2) | SG11201903113TA (enExample) |
| UY (2) | UY37334A (enExample) |
| WO (1) | WO2018076090A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| CR20190379A (es) | 2017-01-30 | 2019-10-21 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| US20210330653A1 (en) | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage Regimen for the Treatment of Cancer |
| PE20221838A1 (es) | 2020-04-24 | 2022-11-29 | Astrazeneca Ab | Formulaciones farmaceuticas |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| WO1995034304A1 (en) * | 1994-06-10 | 1995-12-21 | Nauchno-Issledovatelsky Institut Farmakologii Rossiyskoi Akademii Meditsinskikh Nauk | Pharmacologically active 2-mercaptobenzimidazole derivatives |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| KR100499106B1 (ko) | 1996-12-10 | 2005-07-01 | 브리스톨-마이어즈 스퀴브 컴페니 | 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제 |
| CA2334299A1 (en) | 1998-06-05 | 1999-12-09 | Pierre Dextraze | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| PT1189900E (pt) | 1999-06-30 | 2004-05-31 | Bristol Myers Squibb Co | Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos |
| WO2003062224A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| JP2010503654A (ja) * | 2006-09-12 | 2010-02-04 | ファイザー・プロダクツ・インク | ベンゾイミダゾロン誘導体 |
| JP2010507664A (ja) * | 2006-10-25 | 2010-03-11 | 武田薬品工業株式会社 | ベンズイミダゾール化合物 |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es active IP Right Grant
- 2017-07-19 UY UY0001040644A patent/UY40644A/es not_active Application Discontinuation
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es active IP Right Grant
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en not_active Ceased
- 2017-10-23 PE PE2023002494A patent/PE20250558A1/es unknown
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 ES ES20185268T patent/ES3013994T3/es active Active
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active Active
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760B1/en active Active
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 MX MX2019004782A patent/MX392990B/es unknown
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19032963A (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CL2020003425A1 (es) | Nuevos derivados heterocíclicos útiles como inhibidores de shp2 (divisional solicitud n° 201902698) | |
| CO2020004249A2 (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CL2019002103A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa. | |
| MX388749B (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak. | |
| PA8842101A1 (es) | Heteroarilos sustituidos | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| CY1121898T1 (el) | Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4 | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| EA200701588A1 (ru) | Способы получения замещённых фенилпиразолмочевин | |
| CY1125323T1 (el) | ΚΥΚΛΙΚΑ ΠΑΡΑΓΩΓΑ ΑΙΘΕΡΑ ΤΟΥ ΠΥΡΑΖOΛO[1,5- a]ΠΥΡΙΜΙΔΙΝO-3-ΚΑΡΒOΞΥΑΜΙΔΙOΥ | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
| MX2020006105A (es) | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. | |
| EA201990362A1 (ru) | Аналог вортиоксетина и его применение и получение | |
| BR112018071548A2 (pt) | compostos heterocíclicos bicíclicos substituídos | |
| CR20110628A (es) | Piperidinas sustituidas | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. |